- Home
- CMPS vs ITOS Comparison
CMPS vs ITOS Comparison
Compare CMPS & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPS
- ITOS
- Stock Information
- Founded
- CMPS 2020
- ITOS 2011
- Country
- CMPS United Kingdom
- ITOS United States
- Employees
- CMPS N/A
- ITOS N/A
- Industry
- CMPS Biotechnology: Pharmaceutical Preparations
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CMPS Health Care
- ITOS Health Care
- Exchange
- CMPS Nasdaq
- ITOS Nasdaq
- Market Cap
- CMPS 246.5M
- ITOS 270.7M
- IPO Year
- CMPS 2020
- ITOS 2020
- Fundamental
- Price
- CMPS $3.60
- ITOS $7.15
- Analyst Decision
- CMPS Strong Buy
- ITOS Strong Buy
- Analyst Count
- CMPS 6
- ITOS 3
- Target Price
- CMPS $20.20
- ITOS $26.00
- AVG Volume (30 Days)
- CMPS 836.8K
- ITOS 410.1K
- Earning Date
- CMPS 05-07-2025
- ITOS 05-09-2025
- Dividend Yield
- CMPS N/A
- ITOS N/A
- EPS Growth
- CMPS N/A
- ITOS N/A
- EPS
- CMPS N/A
- ITOS N/A
- Revenue
- CMPS N/A
- ITOS $35,000,000.00
- Revenue This Year
- CMPS N/A
- ITOS N/A
- Revenue Next Year
- CMPS N/A
- ITOS $31.74
- P/E Ratio
- CMPS N/A
- ITOS N/A
- Revenue Growth
- CMPS N/A
- ITOS 177.89
- 52 Week Low
- CMPS $2.49
- ITOS $4.80
- 52 Week High
- CMPS $9.63
- ITOS $18.75
- Technical
- Relative Strength Index (RSI)
- CMPS 60.07
- ITOS 60.28
- Support Level
- CMPS $2.94
- ITOS $4.80
- Resistance Level
- CMPS $3.11
- ITOS $5.55
- Average True Range (ATR)
- CMPS 0.22
- ITOS 0.43
- MACD
- CMPS 0.11
- ITOS 0.20
- Stochastic Oscillator
- CMPS 93.57
- ITOS 97.62
About CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.